New Jersey Clinical Trials Report — July 2026

New Jersey residents considering a clinical trial should check eligibility soon: 98 recruiting studies are expected to close within the next 90 days. Ten of those trials accept healthy volunteers, creating a particularly short window for people without a diagnosed condition. Across the state, 1,659 trials are currently recruiting through 1,073 research sites in 162 cities.

July brought 26 new trials, down from 43 in June and 32 in May. The decline follows a generally uneven six-month pattern: monthly new-trial openings ranged from 26 to 46 during the reported period. Even with fewer launches this month, New Jersey continues to offer a broad mix of cancer, blood-disease, gastrointestinal, kidney, neurological, behavioral, and prevention research.

Closing enrollment puts cancer and healthy-volunteer opportunities on the clock

Breast cancer has the largest number of trials approaching closure, with 6 studies. Multiple myeloma and cervical cancer follow with 4 each. Other prominent areas include cardiovascular diseases, lung cancer, nicotine use disorder, opioid use disorder, central nervous system diseases, blood pressure, and cancer overall.

• Breast cancer — 6 closing-soon trials
• Multiple myeloma and cervical cancer — 4 each
• Cardiovascular diseases — 3
• Lung cancer, nicotine use disorder, opioid use disorder, central nervous system diseases, blood pressure, and cancer — 2 each

People who may qualify should contact study teams promptly rather than waiting until the projected deadline. Screening, medical-record review, laboratory testing, and other enrollment steps can take time, and projected closing dates may change. The ten closing-soon studies that accept healthy volunteers are especially relevant to adults who want to participate without having one of the listed diseases.

July’s new studies span cancer, blood disorders, and chronic disease

The month’s new-trial list is led by drug research, with 13 drug studies. Behavioral studies account for 5, while other intervention types account for 4, biological studies for 3, and diagnostic testing for 1. New conditions include adenocarcinoma of the rectum, acute myeloid leukemia, anemia, grade 2 and grade 3 IDH-mutant astrocytoma, autism spectrum disorder, blood cancer, central nervous system metastasis, and chronic kidney disease.

• Adenocarcinoma of the rectum, acute myeloid leukemia, anemia, autism spectrum disorder, central nervous system metastasis, and chronic kidney disease — 1 new trial each
• Grade 2 and grade 3 IDH-mutant astrocytoma — 1 trial each
• Blood cancer and blood cancers — 1 trial each

Five of the 26 new trials accept healthy volunteers, and 130 healthy-volunteer studies are recruiting statewide overall. This gives healthy adults several ways to participate, although many studies may be online, observational, or focused on databases and prevention rather than testing a new treatment.

Large and notable studies from Novo Nordisk, Bristol-Myers Squibb, and academic sponsors

Several July launches stand out because of their scale, phase, or sponsor. Novo Nordisk A/S is sponsoring NCT07713901, a database linkage study using real-world data to examine whether GLP-1 receptor agonists used for type 2 diabetes and weight management are associated with the risk of medullary thyroid carcinoma. The study lists an anticipated enrollment of 93,600,000 participants, reflecting its use of large health-data resources rather than conventional site-based visits.

Rutgers, The State University of New Jersey, opened NCT07714044, a national genetics study of blood cancers. The study plans to enroll 10,000 affected and unaffected participants through an online portal, surveys, mailed saliva collection, DNA sequencing, and genetic analysis. The Life Raft Group’s NCT07697248 is building a registry of people with gastrointestinal stromal tumors, or GIST, with a planned enrollment of 5,000.

• NCT07713901 — Novo Nordisk’s database linkage study evaluating the risk of medullary thyroid carcinoma among users of GLP-1 receptor agonists.
• NCT07714044 — Rutgers’ online genetics study of blood cancers, including surveys, mailed saliva samples, and DNA analysis.
• NCT07697248 — The Life Raft Group’s GIST patient registry for disease history, outcomes, and research.
• NCT07697456 — AbbVie’s Phase 2 study of advanced therapies for adults with moderately to severely active Crohn’s disease or ulcerative colitis, planning 2,000 participants.
• NCT07680790 — Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study of izalontamab brengitecan with osimertinib for previously untreated EGFR-mutant non-small cell lung cancer, with 850 planned participants.
• NCT07690371 — Nektar Therapeutics’ Phase 3 study of rezpegaldesleukin for participants age 12 and older with moderate-to-severe atopic dermatitis, planning 510 participants.

Other new studies focus on risk prediction and digital tools. Memorial Sloan Kettering Cancer Center is sponsoring NCT07701733, which examines factors associated with lung cancer risk in people who have never smoked. Rutgers is also sponsoring NCT07716527, a pilot study of a web-based tool intended to support lung cancer screening decisions. These studies may appeal to people interested in prevention, screening, genetics, or health technology rather than treatment trials.

New Jersey’s July activity concentrates in several research corridors

New trial openings are concentrated in a group of communities linked to major cancer centers, hospitals, and academic institutions. Basking Ridge, Middletown, and Montvale each recorded 5 new trials. New Brunswick followed with 4, while Hackensack and East Brunswick each added 3. Lawrenceville, Marlton, Union, and East Hanover each recorded 1.

• Basking Ridge, Middletown, and Montvale — 5 new trials each
• New Brunswick — 4
• Hackensack and East Brunswick — 3 each
• Lawrenceville, Marlton, Union, and East Hanover — 1 each

The pattern points to a strong concentration in northern and central New Jersey, particularly around Hackensack, Montvale, Basking Ridge, New Brunswick, and surrounding communities. However, the statewide total of 162 recruiting cities means opportunities extend beyond these leading locations. Residents should search by condition and travel distance, since a large national study may have only one or two participating New Jersey sites.

Who may find an opening this month?

Families should review the six July trials that include children. Three new studies are female-only and one is male-only. Older adults are included in 22 new-trial eligibility criteria, making age-related eligibility a common feature of this month’s research. People with cancer or blood disorders may find the largest concentration of treatment opportunities, while healthy adults can look among the five new studies that accept volunteers without the target condition.

Memorial Sloan Kettering Cancer Center opened 5 new trials, Rutgers opened 3, and Bristol-Myers Squibb opened 2. Other named sponsors include Duboce Biopharmaceuticals, Flare Therapeutics, Hackensack Meridian Health, Insud Pharma, and Kenvue Brands. Overall, 15 new trials were industry-sponsored and 11 were classified as other, a mix that combines commercial drug development with academic, registry, database, behavioral, and health-system research.

For New Jersey patients with breast cancer, multiple myeloma, cervical cancer, lung cancer, or cardiovascular conditions, the immediate priority is reviewing the 98 studies nearing closure. Healthy adults should also act now on the ten closing studies that accept volunteers and consider the five new opportunities opened in July. As the summer progresses, recruitment is likely to keep shifting across New Jersey’s major medical and university corridors, creating new possibilities for people ready to respond quickly.